Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT for Extra-cranial Oligorecurrent Tumors
NCT02410187Phase 2Unknown
- Sponsor
- Korea Cancer Center Hospital
- Start
- Mar 2016
- Primary completion
- Mar 2018
01
Overview
Phase 2, randomised, open-label trial in cancer (2 arms), sponsored by Korea Cancer Center Hospital. Primary endpoint: Progression-Free Survival Rate at 2 years. Status: unknown.
02
Conditions
cancer
Beyond the preview
Go deeper on NCT02410187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02410187.